Evaluation of All'InCath in Peripheral Vasculature Percutaneous Transluminal Angioplasty.

Inclusion Criteria: * Ability to provide Informed Consent * Can also be executed by the legal designated representative or the witness * As per the Principal Investigator's practices as per standard of care, the subject is indicated for PTA in the peripheral vasculature, including iliac, femoral, popliteal, and renal arteries, and any treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. * Male or female \>18 years old. * Life expectancy \>1 year Exclusion Criteria: * Unstable coronary artery disease or any other uncontrolled comorbidity. * Myocardial infarction or stroke within two (2) months before baseline evaluation. * Previous peripheral bypass or procedure that includes the target vessel. * Known, untreated allergy or other contraindications to contrast agents or medications used during or after PTA. * Non-correctable bleeding diathesis, platelet dysfunction, thrombocytopenia, or any other known coagulopathy. * The use of antiplatelet or anticoagulant therapy is contraindicated. * Any planned major surgical or interventional procedure within 30 days after the study procedure. * Females who are breast-feeding or child-bearing potential and not using a medically reliable method of contraception (as defined below) for the entire study duration: * medically reliable contraception defined as: oral, injectable, or implantable contraceptives, intrauterine contraceptive devices, or those not using another method deemed by the Investigator to be sufficiently reliable. * subjects who are surgically sterilized / hysterectomized or post-menopausal for longer than two (2) years are not considered childbearing potential. * Positive pregnancy test result in women of child bearing potential or is breast-feeding. * Incapacitated individuals and those with psychiatric disorders that could interfere with the provision of informed consent, completion of tests, therapy, follow-up or general study compliance. * Participation in another study with investigational drug or device within the 30 days preceding and during the present study.